Piperacillin
Piperacillin, Zosyn (piperacillin) is a small molecule pharmaceutical. Piperacillin was first approved as Pipracil on 1982-01-01. It is used to treat bacterial infections, escherichia coli infections, infectious skin diseases, intraabdominal infections, and pelvic infection amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Combinations
Piperacillin tazobactam, Zosyn (discontinued: Piperacillin tazobactam, Zosyn)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Piperacillin sodium
Piperacillin sodium
+
Tazobactam sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER | B. Braun Medical | N-206056 RX | 2025-04-03 | 3 products, RLD, RS |
| ZOSYN IN PLASTIC CONTAINER | Baxter | N-050750 RX | 1998-02-24 | 3 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| piperacillin and tazobactam | ANDA | 2026-09-22 |
| piperacillin and tazobactam and sodium chloride | New Drug Application | 2026-05-08 |
| piperacillin, tazobactam | ANDA | 2024-08-31 |
| pipracil | 2007-04-24 | |
| zosyn | New Drug Application | 2026-05-15 |
Indications
FDA
EMA
Show 1 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01C: Beta-lactam antibacterials, penicillins
— J01CA: Penicillins with extended spectrum
— J01CA12: Piperacillin
— J01CR: Combinations of penicillins, incl. beta-lactamase inhibitors
— J01CR05: Piperacillin and beta-lactamase inhibitor
Clinical
Clinical Trials
224 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 1 | 5 | 12 | 16 | 15 | 46 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | 2 | 2 | 6 | 10 | 21 | 39 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 2 | 11 | 4 | 9 | 25 |
| Communicable diseases | D003141 | — | — | — | 2 | 6 | 8 | 5 | 20 |
| Bacterial infections | D001424 | — | A49 | 1 | 1 | — | 5 | 13 | 20 |
| Critical illness | D016638 | — | — | — | 1 | — | 1 | 13 | 15 |
| Appendicitis | D001064 | EFO_0007149 | K37 | — | 2 | — | 5 | 6 | 13 |
| Septic shock | D012772 | — | A48.3 | — | — | 3 | 3 | 6 | 12 |
| Toxemia | D014115 | — | — | — | — | 1 | 3 | 7 | 11 |
| Acute kidney injury | D058186 | — | N17 | — | — | — | 3 | 8 | 11 |
Show 42 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthcare-associated pneumonia | D000077299 | — | — | — | 1 | 3 | — | 2 | 5 |
| Covid-19 | D000086382 | — | U07.1 | — | — | 1 | — | 3 | 4 |
| Hematologic neoplasms | D019337 | — | — | — | 1 | 1 | — | 2 | 4 |
| Community-acquired pneumonia | D000098968 | — | — | — | — | 3 | — | — | 3 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | 1 | 1 | — | — | 3 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | — | 3 | — | — | 3 |
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | 2 | 2 | — | — | 3 |
| Bronchitis | D001991 | — | J40 | — | 1 | 1 | — | 1 | 2 |
| Inflammation | D007249 | MP_0001845 | — | — | — | 1 | — | 1 | 2 |
| Environmental biomarkers | D000074062 | — | — | — | — | 1 | — | 1 | 2 |
Show 34 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Systemic inflammatory response syndrome | D018746 | EFO_1001478 | R65.10 | — | 1 | — | — | 1 | 2 |
| Gastrointestinal microbiome | D000069196 | — | — | — | 1 | — | — | — | 1 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | 1 | — | — | — | 1 |
| Otitis media | D010033 | EFO_0004992 | H66.9 | 1 | 1 | — | — | — | 1 |
| Otitis | D010031 | — | — | 1 | 1 | — | — | — | 1 |
| Graft vs host disease | D006086 | — | D89.81 | — | 1 | — | — | — | 1 |
| Cross infection | D003428 | — | — | — | 1 | — | — | — | 1 |
| Pancreatic fistula | D010185 | — | — | — | 1 | — | — | — | 1 |
| Fistula | D005402 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | 1 | 5 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Antibiotic prophylaxis | D019072 | — | — | — | — | — | — | 4 | 4 |
| Pharmacokinetics | D010599 | — | — | — | — | — | — | 3 | 3 |
| Acute disease | D000208 | — | — | — | — | — | — | 2 | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 2 | 2 |
| Drug monitoring | D016903 | — | — | — | — | — | — | 2 | 2 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | — | 2 | 2 |
| Respiratory insufficiency | D012131 | — | J96.9 | — | — | — | — | 2 | 2 |
| Hematopoietic stem cell transplantation | D018380 | — | — | — | — | — | — | 2 | 2 |
| Heart arrest | D006323 | EFO_0009492 | I46 | — | — | — | — | 2 | 2 |
| Gram-positive bacterial infections | D016908 | — | — | — | — | — | — | 2 | 2 |
Show 88 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Piperacillin |
| INN | piperacillin |
| Description | Piperacillin is a penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group. It has a role as an antibacterial drug. It is a penicillin and a penicillin allergen. It is a conjugate acid of a piperacillin(1-). |
| Classification | Small molecule |
| Drug class | penicillins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O |
Identifiers
| PDB | — |
| CAS-ID | 61477-96-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL702 |
| ChEBI ID | 8232 |
| PubChem CID | 43672 |
| DrugBank | DB00319 |
| UNII ID | 9I628532GX (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Zosyn – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Piperacillin
+
Tazobactam
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
Black-box warning for: Piperacillin and tazobactam
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
25,202 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use